Abstract:Flu is an acute respiratory disease caused by influenza viruses. The influenza viruses are classified as Alphainfluenzavirus (influenza A virus, IAV), Betainfluenzavirus (influenza B virus, IBV), Gammainfluenzavirus (influenza C virus, ICV), and Deltainfluenzavirus (influenza D virus, IDV) according to the antigenicity of nucleoproteins (NPs) and matrix (M) proteins in vivo. It is estimated that the seasonal influenza epidemics will cause about 3-5 million cases of serious illness and 290,000-650,000 deaths in the world every year, while influenza A virus is the leading cause of infection and death. Neuraminidase (NA) is one of the most critical targets for the development of anti-influenza virus drugs, and the main drugs clinically applied for the treatment of flu are neuraminidase inhibitors. However, various mutant strains have developed resistance to these inhibitors (For example, the substrains of H274Y in H1N1, H5N1, and E119V in H3N2 have developed resistance to Oseltamivir). Influenza viruses mutate frequently, and new substrains emerge constantly, and the pandemics caused by the new substrains will break out at any time. Therefore, it is urgent to develop new and wide-spectrum influenza virus inhibitors for overcoming the emerging influenza pandemic. Here, we focus on describing the progress of influenza virus inhibitors in clinics and clinical trials to provide a comprehensive reference for the researchers.

Recent Progress on Computer-Aided Inhibitor Design of H5n1 Influenza A Virus

Research Progress on Drug-Resistance of Influenza Virus to Neuraminidase Inhibitors

Research Advances in Human Infection with Avian-Origin Influenza A (H7n9)virus

Recent Advances in Application of Computer-Aided Drug Design in Anti-Influenza A Virus Drug Discovery

Recent advances in neuraminidase inhibitor development as anti-influenza drugs.

Recent advances in the structure-based design of neuraminidase inhibitors as antiinfluenza agents.

Advances in Influenza Virus Sialidase Inhibitors

Binding Mechanism of H5N1 Influenza Virus Neuraminidase with Ligands and Its Implication for Drug Design

Progress of Influenza Viruses and Inhibitors

Recent Progress of Novel Anti-Influenza Entry Inhibitors

Emerging Drug Design Strategies in Anti-Influenza Drug Discovery

Recent progress in rational drug design of neuraminidase inhibitors.

Recent Advances in Computer-aided Antiviral Drug Design Targeting HIV-1 Integrase and Reverse Transcriptase Associated Ribonuclease H

Drug design for Influenza A virus subtype H1N1

Novel Hemagglutinin Inhibitors for H1N1 Influenza Virus Screening from TCM Database

Recent Advances in Anti-Influenza Agents with Neuraminidase As Target

Research progress on human infection with avian influenza H7N9

Potent Inhibitor Design Against H1N1 Swine Influenza: Structure-Based and Molecular Dynamics Analysis for M2 Inhibitors from Traditional Chinese Medicine Database.

The Development History, Structural Composition, and Functions of Influenza Viruses and the Progress of Influenza Virus Inhibitors in Clinics and Clinical Trials

Influenza Virus Cell Entry and Targeted Antiviral Development

Screening from the World'S Largest Tcm Database Against H1n1 Virus